Bafna Pharmaceuticals Ltd vs Par Drugs Chemicals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 137 as of 18 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 yearsThe P/E Ratio of Par Drugs & Chemicals Ltd changed from 6.6 on March 2021 to 7.8 on March 2025 . This represents a CAGR of 3.40% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 yearsThe Market Cap of Par Drugs & Chemicals Ltd changed from ₹ 76.17 crore on March 2021 to ₹ 104.5 crore on March 2025 . This represents a CAGR of 6.53% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 39.51 crore. This represent the decline of -100% The revenue of Par Drugs & Chemicals Ltd for the Mar '26 is ₹ 19.97 crore as compare to the Dec '25 revenue of ₹ 30.67 crore. This represent the decline of -34.89% The ebitda of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 4.27 crore. This represent the decline of -100% The ebitda of Par Drugs & Chemicals Ltd for the Mar '26 is ₹ 1.8 crore as compare to the Dec '25 ebitda of ₹ 7.39 crore. This represent the decline of -75.64% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Par Drugs & Chemicals Ltd changed from ₹ 2.53 crore to ₹ 0.85 crore over 8 quarters. This represents a CAGR of -42.04% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Par Drugs & Chemicals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Par Drugs & Chemicals Ltd

Par Drugs and Chemicals Limited was originally incorporated as a Private Limited Company with the name 'Par Drugs and Chemicals Private Limited' at Bhavnagar, Gujarat on 26 February 1999.
Subsequently, the Company was converted into a Public Limited Company and the name of the Company was changed to 'Par Drugs and Chemicals Limited' on 5 November 2018. The Company began in 1982 under the vision of the founder, Late Shri Vallabhbhai J. Savani.
The Company discontinued its existing pharmaceutical and chemical operations and diversified into an entirely new vertical line of business.
With shareholder approval, the Company is investing in real estate & construction, clean & renewable energy, and capital markets. At present, Company is engaged in manufacturing of Active Pharma Ingredients and fine chemicals (API) for domestic market as well as for exports to international markets.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Par Drugs & Chemicals Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Par Drugs & Chemicals Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 326 Cr while Market cap of Par Drugs & Chemicals Ltd is 107 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Par Drugs & Chemicals Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Par Drugs & Chemicals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Par Drugs & Chemicals Ltd?

As of May 18, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹138.0. On the other hand, Par Drugs & Chemicals Ltd stock price is INR ₹87.29.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Par Drugs & Chemicals Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Par Drugs & Chemicals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.